Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/27/13 | $26,600,000 | Series B |
Domain Associates Forward Ventures MPM Capital RusnanoMedInvest | undisclosed |
| 08/25/15 | $80,000,000 | Series C |
Arrowpoint Partners BioMed Ventures Cormorant Asset Management Delos Capital Fund LP Domain Associates EcoR1 Capital Fidelity Management & Research Company Jennison Associates MPM Capital OrbiMed Advisors RusnanoMedInvest | undisclosed |
